Table 3 Adverse events.
| Adverse event | Number of trials | Crude event rate | RR (95% CI) | RD (95% CI) | I2 (%) | |
|---|---|---|---|---|---|---|
| Latanoprost | Brimonidine | |||||
| Itch/discomfort | 8 | 62/583 | 96/532 | 0.81 (0.40 to 1.61) | −0.02 (−0.11 to 0.06) | 73.1 |
| Hyperemia | 8 | 66/530 | 46/482 | 1.37 (0.84 to 2.25) | 0.04 (−0.02 to 0.10) | 39.2 |
| Eyelid disorder (swelling, blepharitis, laxity) | 5 | 8/341 | 5/308 | 1.61 (0.47 to 5.48) | 0.01 (−0.02 to 0.05) | 10.4 |
| Visual disturbance (photophobia, blurred vision, floaters, diploplia) | 8 | 53/504 | 46/468 | 1.19 (0.88 to 1.61) | 0 (−0.02 to 0.02) | 0 |
| Conjunctival disorder (including conjunctivitis) | 2 | 9/313 | 27/260 | 0.16 (0.01 to 5.09) | −0.08 (−0.18 to 0.01) | 82.3 |
| Keratopathy | 3 | 10/249 | 14/213 | 0.69 (0.24 to 1.96) | −0.03 (−0.07 to 0.01) | 30.5 |
| Dry eye | 4 | 5/149 | 7/152 | 0.76 (0.26 to 2.27) | −0.02 (−0.05 to 0.02) | 0 |
| Hypertrichosis | 1 | 6/182 | 0/145 | 10.37 (0.59 to 182.60) | 0.03 (0 to 0.06) | NA |
| Increased iris pigmentation | 2 | 6/268 | 0/229 | 5.48 (0.65 to 46.50) | 0.03 (−0.04 to 0.10) | 0 |
| Fatigue* | 3 | 3/247 | 11/211 | 0.27 (0.08 to 0.88) | −0.04 (−0.07 to −0.01) | 0 |
| Headache | 4 | 6/362 | 13/327 | 0.43 (0.17 to 1.11) | −0.02 (−0.04 to 0.01) | 0 |
I2, intertrial statistical heterogeneity (Cochran Q test); NA, not available; RD, risk difference.
*Significant.